PDS Biotechnology Corporation has launched VERSATILE-003, a Phase 3 clinical trial for its immunotherapy drug, Versamune® HPV. The trial will evaluate Versamune® HPV combined with pembrolizumab as a first-line treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). The trial aims to enroll approximately 350 patients, comparing the combination therapy to pembrolizumab alone.
This Phase 3 trial holds substantial implications for the treatment landscape of HPV16-positive HNSCC. Current treatment options for recurrent/metastatic disease often have limited efficacy, and this trial could lead to a new standard of care offering improved survival and quality of life for these patients. Positive results could significantly impact clinical practice guidelines, offering a new and potentially more effective first-line treatment. The trial’s focus on overall survival as the primary endpoint underscores the potential for a meaningful advancement in patient outcomes.
VERSATILE-003 is a global, multi-center, randomized, and open-label trial. The primary endpoint is overall survival. Secondary endpoints include objective response rate, progression-free survival, disease control rate, and duration of response. Versamune® HPV, delivered subcutaneously, aims to stimulate HPV16-specific T cells. The FDA has granted Fast Track designation to Versamune® HPV, potentially expediting the review process for a future Biologics License Application.
The initiation of this Phase 3 trial represents a pivotal step for PDS Biotech and the potential future of HNSCC treatment. Positive trial results could lead to regulatory approval and commercialization of Versamune® HPV, positioning PDS Biotech as a key player in the immunotherapy space. This advancement may also encourage further research and development into combination immunotherapies for other cancers, ultimately benefiting a wider patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
